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Abstract: The glycosylphosphatidylinositol-linked GDNF (glial cell derived neurotrophic factor)
receptor alpha (GFRA), a coreceptor that recognizes the GDNF family of ligands, has a crucial role
in the development and maintenance of the nervous system. Of the four identified GFRA isoforms,
GFRA1 specifically recognizes GDNF and is involved in the regulation of proliferation, differentiation,
and migration of neuronal cells. GFRA1 has also been implicated in cancer cell progression and
metastasis. Recent findings show that GFRA1 can contribute to the development of chemoresistance
in osteosarcoma. GFRA1 expression was induced following treatment of osteosarcoma cells with
the popular anticancer drug, cisplatin and induction of GFRA1 expression significantly suppressed
apoptosis mediated by cisplatin in osteosarcoma cells. GFRA1 expression promotes autophagy
by activating the SRC-AMPK signaling axis following cisplatin treatment, resulting in enhanced
osteosarcoma cell survival. GFRA1-induced autophagy promoted tumor growth in mouse xenograft
models, suggesting a novel function of GFRA1 in osteosarcoma chemoresistance.
Keywords: GFRA1; osteosarcoma; chemoresistance; GDNF; RET
1. Introduction
Neurotrophic factors (NTFs) are a family of peptides or small proteins including neurotrophins,
neurokines and the glial cell line-derived neurotrophic factor (GDNF) family of ligands, or GFLs.
NTFs are known as key regulators of neuronal ontogeny, neuronal survival, differentiation, migration,
synapse plasticity and function in both the developing and adult nervous systems. They exert their
signaling through kinases such as receptor tyrosine kinases (RTKs). Since it was characterized in 1993,
the GDNF subfamily of NTFs has been well-studied. The GDNF family consists of GDNF, Neurturin
(NRTN), Artemin (ARTN), and Persephin (PSPN) which are also members of the transforming
growth factor-beta superfamily [1–7]. GDNF was isolated from a glial cell line related to the survival
of midbrain dopaminergic neurons, and its loss is associated with neurodegenerative diseases
like Parkinson’s disease [8]. Mainly, GDNF affects many types of neurons in both the peripheral
(sympathetic, parasympathetic, sensory and enteric neurons) and central nervous systems (midbrain
dopamine neurons and motoneurons) [9,10]. RET (rearranged during transformation) receptor
tyrosine kinase was the first RTK to be identified as a GFL co-receptor in 1996. RET is a single
transmembrane-spanning RTK that is essential to vertebrate development of the central and peripheral
nervous systems, kidney and Peyer’s patch organogenesis, and spermatogenesis [11]. Its mutated
form is found in endocrine human cancers and cases of Hirschsprung disease [12]. However, it was
thought that RET cannot bind directly to GDNF until another GFL co-receptor, GDNF receptor alpha 1
(GFRA1), was identified. Interestingly, the ligand-binding specificity of GFLs is determined by GFRA
proteins that have unique high binding affinities for each GFL. So far, three glycosylphosphatidyl
inositol (GPI)-anchored co-receptors related to GFRA1 have been found: GFRA2, GFRA3 and GFRA4
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(Figure 1) [9]. As shown in Figure 1, GFRA1 directly interacts with GDNF and alternatively, it can
bind ARTN or NRTN; GFRA2 binds with NRTN; GFRA3 interacts with ARTN; and GFRA4 is the
preferential co-receptor for PSPN. Although it has been shown that GFLs bind with their co-receptors,
the mechanisms by which these interactions occur still have not been elucidated. As described in
Figure 2, there are currently two hypothetic modes of interaction between GDNF and RET. In the first
mode, GFLs make dimers and form a high-affinity complex with one of four GFRAs. Each GFL-GFRA
homodimer complex recruits c-RET to a lipid raft, a platform containing receptors and messenger
proteins for signal transduction, which triggers autophosphorylation of specific tyrosine residues
in the kinase domains of RET and intracellular signaling [9]. In the second mode, a pre-associated
complex between GFRA and RET could form the binding site for the GFLs [13]. The physiological
roles and regulatory mechanism of GDNF has been relatively well studied as opposed to ARTN,
NRTN and PSPN which have rarely been reported. As shown in Figure 3, once GDNF/GFRA1/RET
makes a complex, it activates various signaling pathways, such as RAS/MAPK, PI3K/Akt and PLCγ
pathway, which contribute to cell proliferation, adhesion, migration, differentiation and survival
and which contribute to the pathogenesis of both cancer and neuronal disease [14,15]. However,
in a RET-independent pathway, GPI-anchored GFRA1 is localized to lipid rafts in the plasma
membrane and then, the GDNF-GFRA1 complex triggers a Src-dependent signaling pathway, leading
to neuronal differentiation and survival [13]. Once RET was identified, additional attempts to find
other signal-transducing GDNF receptors failed for several years until the Paratcha research group
discovered neural cell adhesion molecule (NCAM) as an alternative signaling co-receptor for GFLs [16].
Indeed, in cultured Schwann cells and cortical neurons, GDNF/GFRA1/p140NCAM complex activates
the cytoplasmic protein tyrosine kinase Fyn and FAK, two downstream mediators of p140NCAM [16].
Figure 1. The interaction of glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs)
with their receptors. Four homodimeric GFLs (GDNF, NRTN, ARTN, and PSPN) recognize their
corresponding GDNF family receptor α (GFRα/GFRA1-4). GDNF specifically binds to GFRA1, NRTN
to GFRA2, ARTN to GFRA3, and PSPN to GFRA4. Dotted arrow indicates cross-interaction of
GFLs with GFRA which has been observed. Binding of GFL with GFRA activates protein tyrosine
kinase RET. Neural cell adhesion molecule (NCAM) has been identified as an alternative signaling
receptor for GFLs. RET also has been known as the representative receptor tyrosine kinases (RTKs)
for these neurotrophic factor receptors. Activation of RET or NCAM via the GFL/GFRA complex is
involved in various physiological functions, such as neuronal cell growth, differentiation, migration,
and osteosarcoma chemoresistance via autophagy. Gray-colored area of the membrane indicates lipid
raft. NRTN, neurturin; ARTN, artemin; PSPN, persephin.
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Figure 2. Two hypothetical modes of RET interaction/stimulation by GFL/GFRA. The extracellular
domain of RET tyrosine kinase binds with GFL/GFRA which is linked to the plasma membrane via
a glycosyl phosphatidylinositol (GPI) anchor. The interaction of RET with GFL/GFRA leads to the
phosphorylation of tyrosine residues located in intracellular domain of RET and activates downstream
signaling pathways. (A) GFL dimer binds to the GPI-anchored GFRA in lipid rafts and recruits RET;
(B) GFRA without ligand forms a complex with RET that can serve as a receptor for GFL dimer.
Figure 3. Cont.
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Figure 3. Schematic presentation of regulatory mechanisms of GFL-GFRA1 signaling. (A) RET is
recruited to the lipid microdomain (or lipid rafts) by GPI-anchored GFRA1 (left side, cis-signaling)
and by soluble GFRA1 (right side, sGFRA1, trans-signaling) released from plasma membrane. During
cis-signaling, GFRA1 is anchored to lipid rafts by GPI, allowing GFLs to bind to GFRA1 to transduce
their signals to co-receptor RET which can then activate downstream targets like Src kinase, PLCγ,
or PI3K/AKT. Trans-signaling occurs when the GDNF/sGFRA1 complex binds to RET on another
peripheral neuron which does not express GFRA1. GDNF/sGFRA1/RET can then transduce their
signal to downstream targets such as PI3K/AKT and PLCγ/Cdk5, resulting in neuronal survival
and neurite outgrowth; (B) In the absence of GFLs, short-range signaling by homophilic interactions
between p140NCAM can be disrupted by the presence of GFRA, resulting in the inhibition of cell
adhesion, or extracellular signaling crosstalk (left side). In the presence GFLs, the association of
membrane-bound GFRA with p140NCAM results in the activation of the Fyn-FAK-MAPK signaling
pathway (right side); (C) Ligand-induced cell adhesion; (D) Recycling of GDNF/GFRA1/RET
complex by SorLA. SorLA/GFRA1-mediated GDNF uptake occurs by RET-independent endocytosis.
SorLA/GFRA1 complex directs GDNF to lysosome. SorLA/GFRA1-mediated RET endocytosis is
independent of GDNF.
Until now, GDNF/GFRA1 signaling has been regarded as an emerging potential therapeutic
target in neuronal disease. However, recent studies have reported that GFRA1 also is implicated
in cancer signaling. Moreover, our recent research with osteosarcoma demonstrated that GFRA1
promotes cell survival against the well-known anticancer agent cisplatin by promoting autophagy,
a novel resistance mechanism against chemotherapy. In this review, we summarize the current studies
and focus on the physiological role of GFRA1 in chemoresistance.
2. Regulatory Mechanisms of GDNF/GFRA1 Signaling
Since GDNF was initially identified as a survival factor for midbrain dopaminergic neurons,
it has been investigated in regards to various neural developmental processes, including kidney
morphogenesis and spermatogenesis [11,17–19]. GDNF signaling is much more complex than initially
expected due to the complexity of interaction among GDNF and its co-receptors. This section will
briefly summarize the regulatory mechanisms for GDNF signaling and its receptors.
2.1. GFRA1-RET Signaling
GFRA1-RET signal transduction can be divided into two pathways: cis-signaling and
trans-signaling. As described in Figure 3A, cis-signaling is an action mechanism that occurs on the
same membrane. GPI-anchored GFRA1 is localized to a specialized plasma membrane microdomain,
or lipid rafts. Once GFLs bind to GFRA1, it transfers its signals to co-receptor RET which can
activate downstream targets like Src kinase, RAS/MAPK, PLCγ, or PI3K/AKT, resulting in cell
proliferation, migration and survival in cancer and neuronal cells [20]. Trans-signaling is referred to as
Int. J. Mol. Sci. 2018, 19, 1078 5 of 14
non-cell-autonomous action at a distance (Figure 3A). Soluble GFRA1 (sGFRA1) is constitutively
released by phospholipases and shed from the cell surface. sGFRA1 binds to GDNF with high
affinity and is stably-floated. Once in complex, sGFRA1/GDNF promotes neuronal survival and
neurite outgrowth by binding with RET on the membrane of GFRA1-deficient RET-expressing
cells [21]. The discovery of sGFRA1 in both Schwann cells and injured sciatic nerves opens the
possibility that lesioned peripheral nerves can be readily recovered through GDNF/sGFRA1/Cdk5
axis-axon-guidance activities provided by the adjacent Schwann cells [21,22].
2.2. GFRA1-NCAM Signaling
Neural cell adhesion molecule (NCAM) is a hemophilic binding glycoprotein expressed on the
surface of neurons, glia and skeletal muscle [23–28]. It also has been found to be expressed in the
immune cells including natural killer cells, gamma delta T cells, activated CD8+ T cells and dendritic
cells [29–31]. Alternative mRNA splicing of the NCAM gene produces three isoforms: p120, p140,
p180 [32]. Studies have shown that NCAM plays critical roles in cell-cell adhesion, neurite outgrowth,
neuronal survival, synapse formation and synaptic plasticity [16,33,34]. Interestingly, the presence of
GDNF/GFRA1 is required for NCAM-mediated neuronal signal transduction. Given that NCAM is
an alternative signaling receptor for GFLs, recent investigations of NCAM have been focused on the
clarification of novel mechanisms that could be applied towards successful clinical trials using GDNF
or GFRA1 [16]. Homophilic binding occurs between NCAM molecules on opposing surface (trans-)
and on same surface (cis-). As shown in Figure 3B, dimerization of NCAM functions in neurite growth
via FAK and Fyn, two mediators downstream of NCAM [16]. As a negative regulator, GFRA1 can
inhibit the interaction between NCAM molecules in the absence of GDNF (Short-range). However,
once GDNF is infused from outside, GFRA1 promotes extracellular crosstalk by helping GDNF to
bind with NCAM (Long-range). As will be described in the next regulatory mechanism, in vivo the
NCAM-deficient model shows abnormality of size in the olfactory bulb (OB) caused by defects in
neuronal cell migration in the rostral migratory stream (RMS). Interestingly, overexpression of GDNF
or NCAM in RET-deficient mice recover the size of OB. The results indicate that RET-independent
GDNF signaling via NCAM can play a role in the migration and guidance of neuroblasts and in the
development of the RMS-OB [16].
2.3. GDNF-GFRA1 Signaling: Ligand-Induced Cell Adhesion
Unlike other cell-adhesion molecules (CAMs) trans-interacting among cells, GFRA1-mediated cell
adhesion requires the presence of GDNF. As such, GFRA1 is sometimes referred to as a ligand-induced
cell-adhesion molecule (LICAM). In this case, GPI-anchored GFRA1 and soluble GDNF form a complex
that induces cell adhesion working in a similar status (Figure 3C). Although the means by which
GDNF-induced trans-homophilic interactions occur are not clear, GFRA1-knockout mutants indicate
that GDNF-induced cell adhesion is required for the linkage between GFRA1 and GDNF. Thus,
this mechanism plays a role in the development of the nervous system by permitting the interaction
between neuronal and glial cells [35].
2.4. GFRA1-SorLA Signaling
Until now, the mechanism of GDNF downregulation has not been studied, unlike degradation by
ubiquitination. Recently, the Glerup group demonstrated that SorLA (sorting protein-related receptor)
binds to GFRA1 or RET, which induces GDNF/GFRA1 recycling (Figure 3D). In this process, SorLA
plays a role as a co-receptor of GDNF. Indeed, SorLA has much higher affinity for GDNF/GFRA1 than
RET for endocytosis, but it does not degrade GFRA1. While SorLA mediates GFRA1 recycling through
the endosome, GDNF is transferred to the lysosome for degradation. In SorLA-deficient mice, the level
of GDNF protein is elevated with abnormal GDNF activity [36]. The findings showed a novel role for
GFRA1 in that it is involved in the degradation of GDNF through its binding to SorLA, which induces
GDNF/GFRA1 recycling through endocytosis.
Int. J. Mol. Sci. 2018, 19, 1078 6 of 14
3. Physiological Roles of GFRA1 in Disease
GDNF was purified and characterized as a survival factor of the embryonic dopaminergic
neurons of the midbrain, which degenerate in Parkinson’s disease [8]. In addition, it works as a
potent neurotrophic factor for spinal motor neurons [37]. Thanks to its robust role in the neuron,
GDNF is regarded as a highly promising therapeutic agent for the treatment of neurodegenerative
disease. Although phase I clinical trials with Parkinson’s patients using direct infusions into the
putamen were very effective, phase II studies resulted in conflicting outcomes [38,39]. As previously
mentioned, GFRA1 is a GPI-anchored cell surface receptor for GDNF, NRTN and ARTN. The effect
of GFRA1 signaling can be determined by a variety of interactions and its expression levels. In other
words, its aberrant expression or mutation of co-receptors may cause the abnormalities in neuronal
survival and differentiation. Thus, the key to combating GFL/GFRA1-related disease is to understand
the widespread expression of GFRA1 proteins in various tissues in combination with and without
RET signaling.
In certain types of neurons, the RET-associated GFL/GFRA1 complex activates several
intracellular signaling cascades, which regulate cell survival, differentiation, proliferation, migration,
chemotaxis, branching morphogenesis, neurite outgrowth and synaptic plasticity. Our previous
report demonstrated that GFRA1 overexpression is associated with advanced pancreatic cancer [40].
APE1 (apurinic/apyrimidinic endodeoxynuclease 1)-induced GFRA1 protein forms a complex
with RET through a lipid raft, which stimulates cell proliferation and migration in pancreatic
cancer. Additionally, GFRA1 expression increases neurite outgrowth and survival against β-amyloid
peptide accumulation in neuronal cell lines [41]. In other words, loss of GFRA1 is implicated in
neurodegenerative disease, such as Alzheimer’s (AD) and Parkinson’s disease (PD) [41]. Mutations
in RET are common in Hirschsprung’s disease which is characterized by the absence of neuronal
ganglia in various parts of the colon, leading to severe constipation and intestinal obstruction
during childhood [42]. Although a GFRA1 mutation has not been found in Hirschsprung’s patients,
Hirschsprung’s disease has been observed in heterozygous GDNF+/−mice [43]. However, mutated
GDNF does not reduce the activation of RET [44]. Interestingly, mutated NRTN has also been shown
to be involved in this disease. Collectively, the results imply that mutation in GDNF, NRTN or RET
reduce the affinity for GFRA1 interaction, resulting in Hirschsprung’s disease [43,45,46].
In the RET-independent pathway, there are two possibilities for GFRA signaling: (1) use
of other receptor systems (NCAM, SorLA, Syndecan, MET, ErbB4) or (2) direct GFL/GFRA1
signaling through cytosolic tyrosine kinases, like Src [47–49]. For example, GDNF/GFRA1 signaling
via NCAM contributes to the regulation/modulation of the process of neuronal development,
including proliferation, neuronal fate specification, differentiation, neurite outgrowth, and synapse
formation [50–53]. In contrast, GFRA1 can act to antagonize NCAM-mediated cell adhesion, which
directly acts between GFRA1 and the 4th domain of NCAM [54]. Independently of NCAM, GFRA1
can also act as a cell adhesion molecule by itself, which is termed ligand-mediated cell adhesion [35].
Syndecan-3 is implicated in GDNF signaling through its heparan sulfate chains [47]. In GABAergic
interneurons of the medial ganglionic eminence (MGE), GDNF signaling can transfer via MET or
ErbB4 [48,49].
As mentioned above, most studies of GDNF/GFRA1 signaling are related to neurodegenerative
(Parkinson’s disease and Alzheimer’s disease) and neuropsychiatric diseases (addiction, bipolar
disorder, obsessive compulsive disorder, depression, anxiety, autism, schizophrenia, and attention
deficit hyperactivity disorder). Moreover, recent therapeutic approaches for GDNF/GFRA1 signaling
are intended to investigate how GDNF is infused to target cells or to find what can interact with
GFRA1 [55]. In the brain dopamine system, GDNF-based therapy is rising in treatment of Parkinson’s
disease (PD) which is caused by cell death in the substania nigra pars compata (SNpc) of the midbrain,
due to loss of dopamine [56]. SNpc contains about 10,000–15,000 dopaminergic neurons which express
GFRA1 and RET [57]. Recent PD models show the symptom after more than 50% of striatal dopamine
levels and 30–40% of SNpc neurons are lost [58]. Additionally, rodent models of PD demonstrate
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that the axonal trees of the remaining axons can re-innervate the striatal areas left vacant by the
degenerating dopaminergic neurons to inhibit or reverse the progression of PD via GDNF delivery [58].
Moreover, the recent rodent models for ectopic overexpression of GDNF or GFRA1 in the forebrain of
mice using a neuron-specific CAMKII promoter demonstrates that endogenous GDNF is essentially
required for midbrain dopaminergic neuron development of maintenance [59,60]. Subsequently, the
successes and draw-backs of GDNF-based therapies in PD need a physiological understanding of
GDNF/GFRA1 signaling in vivo.
GDNF and its receptors have been shown to be concentrated within the midbrain. However, they
are often observed in many other brain regions in the CNS. Recent studies show that GDNF and its
two receptors (GFRA1 and NCAM) are expressed by hippocampal neurons during embryonic and
early postnatal stages [22,35,61]. In other words, GFRA1 functions as a ligand-induced cell adhesion
molecule at synaptic sites, which promotes cell-to-cell interaction for communication among cells. Once
abnormal expression of GFRA1 or NCACM decreases presynaptic maturation during hippocampal
synaptogenesis, neuropsychiatric disorders can occur [22,61]. In GABAergic neurons, GFRA1 signaling
plays a critical role in the development of the olfactory system. Although GFRA1 itself was not
expressed by matured GABAergic neurons in the olfactory bulb (OB), all major classes of GABAergic
interneurons are reduced or deficient by non-cell-autonomous functions of GFRA1 in other factors
of the olfactory system [62]. In addition, the upregulation of GDNF and GFRA1 has been reported
in stroke (ischemia) and epilepsy (seizure disorder) [63,64]. In contrast, GDNF levels were found
to be decreased in Alzheimer’s disease (AD), leading to progressive loss of cognitive function and
dementia [65]. In fact, despite occurring in more than 10% of people after the age of 65, AD diagnosis
in early stages is still difficult. Importantly, a recent study showed that GDNF was found as one of 18
signaling proteins identified in blood from 250 AD patients [66]. As mentioned earlier, recent AD studies
suggest that GDNF increases the survival of cells by promoting the release of β-amyloid peptide from
neuron-like cells, without increased expression of amyloid protein precursor (APP) or secretase [40,65].
Intriguingly, recent studies of neuropsychiatric disorders have reported that increased protein levels of
GDNF or its polymorphism were observed in addiction, bipolar disorder, obsessive compulsive disorder,
autism, schizophrenia, and attention deficit hyperactivity disorder [67–71]. In contrast, the protein
levels of GDNF and its receptor GFRA1 were reduced in depression. In particular, downregulation of
GFRA1a was associated with increased expression of microRNAs. Further studies showed that miR-511,
which targets long 3′ untranslated region-containing transcripts coding for GFRA1a, repressed GFRA1a
expression in human neural progenitor cells without altering GFRA1b expression, suggesting that
microRNAs are involved in the modulation of GDNF/GFRA1 signaling [72].
Taken together, these findings demonstrate that clarification of the emerging roles of
GDNF/GFRA1 signaling in CNS and PNS is essential to the development of biomarkers to accurately
diagnose and drugs to treat these neuronal diseases.
4. GFRA1 in Cancer
Given the function of GFRA1 in neuronal development, GFRA1 has been studied with eyes on
the emerging therapeutic treatment in neuronal disease, especially Parkinson’s disease. However,
recent evidence suggests that GFRA1 is robustly involved in cancer progression [73]. Indeed, aberrant
GDNF or GFRA1 expression has been often found in various cancer cells including those of the
pancreas, skin and breast, as well is in osteosarcoma (Table 1). Recent studies provide evidence
that GFRA1 is implicated in tumorigenesis and cancer progression. One research group showed
that GFRA1 and RET are overexpressed in estrogen receptor-positive (ER+) tumors by screening a
tissue microarray of invasive breast cancer. We further investigated whether tumor progression in
these tumors is driven by the expression of GFRA1 and RET receptors or GDNF which is regulated
in response to the inflammatory microenvironment surrounding many epithelial cancers. In tumor
xenografts, they showed that the inflammatory cytokines tumor necrosis factor-α and interleukin-1β act
synergistically to up-regulate GDNF expression and this effect is mediated by a GDNF/GFRA1/RET
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axis [74]. Another research group found that circular GFRA1 RNA (circGFRA1) regulates GFRA1
expression through sponging miR-34a to exert regulatory functions in triple negative breast cancer
(TNBC) [75]. Their findings imply circGFRA1 may be a potential biomarker and/or therapeutic target
for TNBC. Our study showed that GFRA1 expression is regulated by nuclear factor kappa B (NFκB) in
pancreatic cancer. GDNF/GFRA1/RET signaling promotes cell proliferation and migration through
SRC and MMP signaling [40]. Unlike neuronal cells, GFRA1 overexpression induces tumor progression
in cancer cells. Collectively, the results from these investigations provide support to the idea that
GFRA1 may be applicable as a biomarker and/or therapeutic target for cancer. Further understanding
of GFRA1 expression will provide a major clue to solve the riddle of cell outcome, neuronal cell death
and cancer cell proliferation and survival.
Table 1. The expression of GDNF ligands and its receptors in cancer cells.
Type of Ligand Type of Receptor Biological Functions Type of Cancer References
ARTN GFRA1/GFRA3 ND mammary carcinoma [76]
GDNF RET/GFRA1 ND Breast cancer [74]
GDNF RET/GFRA1 Oncogenicity malignant melanoma [77]
GDNF RET/GFRA1 Aromatase inhibitor resistance Breast cancer [78]
ND GFRA1 Cisplatin resistance by autophagy Osteosarcoma [73]
ND GFRA1 ND Breast cancer [79]
ND GFRA1 ND Breast cancer [75]
GDNF GFRA1 Cell migration and proliferation Pancreatic cancer [40]
ARTN, artemin; GDNF, glial cell-line-derived neurotrophic factor; GFRA1, GDNF receptor alpha 1; GFRA3, GDNF
receptor alpha 3; RET, rearranged during transformation; ND, not determined.
5. Emerging Roles of GFRA1 in Chemoresistance
Although osteosarcoma is not a common cancer, it is a serious disease given that the most affected
age group are children and adolescents [80]. In addition, despite the fact that the long-term survival rate
has increased to approximately 70% thanks to the use of adjuvant therapy, about 10–20% of patients have
tumors which have already metastasized [81]. Indeed, it could be said that the success and draw-back
of chemotherapy is dependent on the resistance of cells to the drug used. To date, cisplatin is the most
widely used platinum-based anticancer drug for solid tumors [82]. It interacts with nucleophilic N7
sites of purine bases in DNA to induce DNA damage which leads to inhibition of tumor cell division
and initiation of apoptosis, or programmed cell death [83]. However, due to the resistance of cells to
cisplatin and drug toxicity, use of a combination therapy of methotrexate, doxorubicin and cisplatin has
become common practice. Chemoresistance can be caused by the failure of drug export, DNA repair
mechanisms, cancer stem cells, apoptotic signaling, or self-sufficiency for growth factor signaling [84].
Thus, understanding the mechanism of chemoresistance development may facilitate early detection,
diagnosis and prognosis, thereby making it essential to treat cancer more effectively.
Autophagy is known as a self-digest mechanism for recycling the unnecessary and dysfunctional
components to maintain homeostasis of cells [85,86]. At first, it was regarded as an alternative cell
death mechanism known as programmed cell death II [87–89]. However, recent paradoxical findings
demonstrated that autophagy also can play a role in cell survival against environmental stresses including
nutrient deficiency, chemotherapy, radiation, and hypoxia [87,88,90]. Currently, the roles of autophagy
in either apoptotic cell death as a tumor suppressive mechanism or cell survival mechanisms remain
mostly controversial. Moreover, the regulatory mechanism of autophagy in chemoresistance has rarely
been studied. Recently, our study demonstrated that GFRA1 induces autophagy as a novel regulatory
mechanism of osteosarcoma chemoresistance; although neither ligand nor GFRA1 coreceptor were
identified in this study, we found cisplatin triggers GFRA1 expression through NFκB [73]. The level of
GFRA1 expression was increased in two osteosarcoma cell lines, MG-63 and U-2 OS, following treatment
with cisplatin at both transcriptional and translational levels. However, two other chemotherapeutic
drugs that were used for osteosarcoma treatment, doxorubicin and methotrexate, did not induce GFRA1
expression, indicating that cisplatin specifically induces GFRA1 expression. However, we do not exclude
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the possibility that other chemotherapeutic drugs can also induce GFRA1 expression in other types
of cells as well as osteosarcoma cells. Previous studies have shown that NFκB upregulates GFRA1
mRNA expression through transcriptional activation [40]. Consistent with this finding, the levels
of NFκB and phosphorylated NFκB expression were increased in osteosarcoma cells after cisplatin
treatment compared to untreated cells. Inhibition of NFκB expression significantly reduced GFRA1
expression, suggesting that cisplatin-mediated activation of NFκB is one critical signaling pathway for
GFRA1 expression [73]. Knockdown of GFRA1 expression in osteosarcoma cells significantly increased
cisplatin-induced apoptosis, while overexpression of GFRA1 reduced cisplatin-induced apoptosis. Further
studies showed that cisplatin treatment significantly increased autophagy in osteosarcoma cells, whereas
it was not observed in GFRA1-deficient cells. GFRA1 overexpression in osteosarcoma cells significantly
increased cell proliferation in the presence or absence of cisplatin with increased autophagy compared
to control cells and this effect was blocked by the inhibition of autophagy. Src is one of the downstream
targets of GFRA1 signaling [9]. Mechanistic studies showed that Src phosphorylation was increased in
osteosarcoma cells with increased GFRA1 expression following cisplatin treatment and subsequently
increased AMP-activated protein kinase (AMPK) phosphorylation, which is involved in the regulation
of autophagy. Activated Src/AMPK signaling by GFRA1 increased the expression levels of beclin
1, high mobility group box 1 (HMGB1), and microtubule-associated protein light chain 3-II (LC3-II),
which are downstream molecules involved in autophagy, suggesting that cisplatin-induced GFRA1
vertically transferred its survival signal to autophagy molecules through the Src/AMPK pathway
(Figure 4). GDNF is the major ligand of GFRA1 as described above. However, GDNF had no effect
on osteosarcoma cell survival after cisplatin treatment. This result implies that cisplatin-mediated
activation of GFRA1 signaling is independent of GDNF. In addition, RET, a coreceptor of GDNF, was
not expressed in osteosarcoma cells [73]. Mouse xenograft studies showed that mice injected with
GFRA1-overexpressing osteosarcoma cells started to develop tumors 5 days after injection and produced
large-sized tumors (~90 mm3). In contrast, mice injected with control osteosarcoma cells did not develop
tumors until 17 days after injection and the resultant tumors were small (~10 mm3). Treatment of mice
with chloroquine, an autophagic inhibitor, in combination with cisplatin significantly reduced tumor
volume compared with PBS, chloroquine, or cisplatin-treated mice. Interestingly, we found that four out
of nine osteosarcoma patients whose tumors were metastasized to the lung were positive for both GFRA1
and HMGB1 expression. These results showed that GFRA1-mediated autophagy is associated with cancer
cell survival/tumor progression in patients that did not respond to cisplatin treatment [73]. In summary,
our data showed that GFRA1 plays a critical role in cisplatin-induced chemoresistance via autophagy and
it suggests that GFRA1 may be a potential therapeutic target against chemoresistance.
Figure 4. Schematic diagram for autophagy mediated by GFRA1 in cisplatin-resistant osteosarcoma.
Cisplatin induces GFRA1 through NFκB, and GFRA1 activates autophagy by SRC/AMPK signaling.
Finally, GFRA1-mediated autophagy inhibits cisplatin-induced apoptosis, resulting in cell proliferation
and migration.
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6. Conclusions
Although studies of GDNF family ligands and their receptors reveal that they are emerging
targets for neuronal disease and cancer therapy, the complexity of their signaling still remains
unclear. GFLs and GFRA1 expression levels may be dependent on their specific roles in cells.
In addition, the choice between GDNF ligand family and GFRA1 also may determine their function.
In other words, because cell-to-cell interaction is required for the communication of neuronal cells,
GDNF/GFRA1 levels may be increased. Definitely, the discovery of sGFRA provides a clue as to how
GDNF ligands and co-receptors can physiologically interact at a distance. The loss of GDNF/GFRA1
in the neuron inhibits its development, such as synapse formation in neuronal cells. Similarly,
aberrant expression of GFRA1 has been often observed in cancer. Furthermore, GFRA1 expression is
elevated by cisplatin treatment in osteosarcoma cells. GFRA1-mediated signaling activated autophagy,
resulting in hyperproliferation, cell survival and metastasis in osteosarcoma. Taken together, a further
understanding of the mechanisms involving GFRA1 may provide critical information towards
discovering novel potential therapeutic approaches for overcoming chemoresistance in osteosarcoma.
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